Background: Obese insulin-resistance is one of the most important risk factor for cardiovascular diseases including ischemic heart disease (IHD). Growing evidences suggest that the susceptibility to myocardial ischemia-reperfusion (I/R) injury is increased in an obese insulin-resistance condition. Based on the currently available evidence from human and animal studies, this review mainly focuses on the influence of obese insulinresistance on the outcome of the I/R insult to the heart. Moreover, we have discussed whether improving insulin sensitivity by pharmacological interventions could ameliorate reperfusion induced myocardial injury.
Methods: The electronic database Pubmed was used as the source of selected peerreviewed research articles published in English. Both pre-clinical studies and clinical trials were obtained using obesity, insulin resistance, ischemia-reperfusion injury and myocardial infarction as keywords.
Results: Twenty-seven pre-clinical studies were obtained using obesity, insulin resistance, and cardiac ischemia-reperfusion injury as keywords, and five clinical trials were obtained using obesity, insulin resistance, and myocardial infarction as keywords. The underlying mechanisms responsible for the exacerbation of I/R injury in obese insulinresistance were the main subject of our review.
Conclusion: The findings of this review suggest that the susceptibility to I/R injury is increased in an obese insulin-resistance condition. However, the underlying mechanisms responsible for the exacerbation of I/R injury in obese insulin-resistance have not been fully elucidated, but increased basal oxidative stress, the impairment of anti-oxidant capacities, insulin signaling and pro-survival signaling and increased inflammation, likely play an important role.
Keywords: Obese insulin-resistance, ischemia/reperfusion, heart, myocardial infarction, ishemic heart disease, obesity.
Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning
Current Neuropharmacology Diabetes, Oxidative Stress, Nitric Oxide and Mitochondria Function
Current Diabetes Reviews Human Ghrelin: A Gastric Hormone with Cardiovascular Properties
Current Pharmaceutical Design Development of Nitric Oxide Donors for the Treatment of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Pro-rich Antimicrobial Peptides from Animals: Structure, Biological Functions and Mechanism of Action
Current Pharmaceutical Design Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology New Therapeutic Strategies in Perinatal Stroke
Current Drug Targets - CNS & Neurological Disorders Renal Endothelial Dysfunction in Acute Kidney Ischemia Reperfusion Injury
Cardiovascular & Hematological Disorders-Drug Targets Cardioprotection Against Ischemia/Reperfusion Injury and Chromogranin ADerived Peptides
Current Medicinal Chemistry Protective Effect of Natural Antioxidants on Heart Against Ischemia-Reperfusion Damage
Current Pharmaceutical Biotechnology Hypercoagulability in Sickle Cell Disease and Beta-Thalassemia
Current Molecular Medicine Cardioprotection by Regular Ethanol Consumption: Potential Mechanisms and Clinical Application
Current Drug Abuse Reviews Gene Therapy for Heart Transplantation-Associated Acute Rejection, Ischemia / Reperfusion Injury and Coronary Arteriosclerosis
Current Gene Therapy NQDI 1, An Inhibitor of ASK1 Attenuates Acute Ischemic Renal Injury by Modulating Oxidative Stress and Cell Death
Cardiovascular & Hematological Agents in Medicinal Chemistry The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets The Roles of Cytochrome P450 in Ischemic Heart Disease
Current Drug Metabolism Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Current Pharmaceutical Design Reactive Oxygen Species, Vascular Disease and Cardiovascular Surgery
Current Vascular Pharmacology Inhibition of sPLA2-IIA, C-reactive Protein or Complement: New Therapy for Patients with Acute Myocardial Infarction?
Cardiovascular & Hematological Disorders-Drug Targets